[go: up one dir, main page]

DK1809622T3 - Inhibitorer af interaktionen mellem MDM2 og P53 - Google Patents

Inhibitorer af interaktionen mellem MDM2 og P53

Info

Publication number
DK1809622T3
DK1809622T3 DK05786991.9T DK05786991T DK1809622T3 DK 1809622 T3 DK1809622 T3 DK 1809622T3 DK 05786991 T DK05786991 T DK 05786991T DK 1809622 T3 DK1809622 T3 DK 1809622T3
Authority
DK
Denmark
Prior art keywords
mdm2
inhibitors
interaction
Prior art date
Application number
DK05786991.9T
Other languages
English (en)
Inventor
Jean Fernand Armand Lacrampe
Christophe Meyer
Yannick Aime Eddy Ligny
Imre Christian Francis Csoka
Hijfte Luc Van
Janine Arts
Bruno Schoentjes
Camille Georges Wermuth
Bruno Giethlen
Jean-Marie Contreras
Muriel Joubert
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1809622(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1809622T3 publication Critical patent/DK1809622T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK05786991.9T 2004-09-22 2005-09-16 Inhibitorer af interaktionen mellem MDM2 og P53 DK1809622T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04077630 2004-09-22
US61390204P 2004-09-28 2004-09-28
PCT/EP2005/054604 WO2006032631A1 (en) 2004-09-22 2005-09-16 Inhibitors of the interaction between mdm2 and p53

Publications (1)

Publication Number Publication Date
DK1809622T3 true DK1809622T3 (da) 2010-11-08

Family

ID=34928531

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05786991.9T DK1809622T3 (da) 2004-09-22 2005-09-16 Inhibitorer af interaktionen mellem MDM2 og P53

Country Status (30)

Country Link
US (2) US7834016B2 (da)
EP (1) EP1809622B1 (da)
JP (1) JP5156378B2 (da)
KR (1) KR101331786B1 (da)
CN (1) CN101023074B (da)
AP (1) AP2446A (da)
AR (1) AR053412A1 (da)
AT (1) ATE474833T1 (da)
AU (1) AU2005286525B2 (da)
BR (1) BRPI0515594B8 (da)
CA (1) CA2579915C (da)
CR (1) CR9081A (da)
DE (1) DE602005022472D1 (da)
DK (1) DK1809622T3 (da)
EA (1) EA012452B1 (da)
EC (1) ECSP077335A (da)
ES (1) ES2349358T3 (da)
HK (1) HK1107651A1 (da)
HR (1) HRP20100561T1 (da)
IL (1) IL182009A (da)
MX (1) MX2007003375A (da)
MY (1) MY136800A (da)
NO (1) NO341281B1 (da)
NZ (1) NZ553646A (da)
SG (1) SG155941A1 (da)
SI (1) SI1809622T1 (da)
TW (1) TWI372758B (da)
UA (1) UA91027C2 (da)
WO (1) WO2006032631A1 (da)
ZA (1) ZA200702341B (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1928454T1 (sl) 2005-05-10 2015-01-30 Intermune, Inc. Piridonski derivati za moduliranje s stresom aktiviranega protein kinaznega sistema
EP1881983B1 (en) * 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridines useful as inhibitors of protein kinase
JP5385125B2 (ja) * 2006-03-22 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
US8088795B2 (en) * 2006-03-22 2012-01-03 Janssen Pharmaceutica N.V. Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53
JP5269761B2 (ja) * 2006-04-12 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション ピリジルアミドｔ型カルシウムチャンネルアンタゴニスト
BRPI0713253A2 (pt) 2006-07-07 2012-10-30 Steven P Govek método de inibição de pde4, método de tratamento de um doença mediada por pde4, composto e composição farmacêutica
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
WO2008121442A2 (en) * 2007-02-09 2008-10-09 The Uab Research Foundation Pa28-gamma regulation in cells
US20100129933A1 (en) * 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
EP2185541B1 (en) * 2007-08-06 2015-01-28 Janssen Pharmaceutica, N.V. Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
WO2009037343A1 (en) 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
RU2010120671A (ru) 2007-10-24 2011-11-27 Мерк Шарп Энд Домэ Корп. (Us) Гетероциклические фениламидные антагонисты кальциевых каналов т-типа
US8268777B2 (en) * 2007-12-05 2012-09-18 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
EP2224920A4 (en) * 2007-12-06 2012-05-09 Enanta Pharm Inc PROCESS FOR THE PREPARATION OF MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
WO2009149188A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EA021883B1 (ru) 2009-02-04 2015-09-30 Янссен Фармацевтика Нв Производные индола в качестве противораковых агентов
US20120135089A1 (en) * 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
NZ600430A (en) 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists
PH12012501337A1 (en) 2009-12-30 2012-12-17 Arqule Inc Substituted pyrrolo-aminopyrimidine compounds
US20130102631A1 (en) * 2010-07-02 2013-04-25 Syngenta Crop Protection Llc Novel microbiocidal dioxime ether derivatives
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
CN103298818B (zh) 2010-11-12 2016-06-29 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
CN103717605B (zh) 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂
UY34591A (es) * 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2509808C1 (ru) * 2012-10-30 2014-03-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) СПОСОБ ОПРЕДЕЛЕНИЯ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКИХ К ДЕЙСТВИЮ ПРЕПАРАТОВ, РЕАКТИВИРУЮЩИХ БЕЛОК р53
KR20140059002A (ko) * 2012-11-07 2014-05-15 한국과학기술원 다제내성 종양 치료를 위한 항암제 및 치료방법
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EA031804B1 (ru) 2014-02-03 2019-02-28 Вайтаи Фармасьютиклз, Инк. Дигидропирролопиридиновые ингибиторы ror-гамма
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
UA118989C2 (uk) 2014-10-14 2019-04-10 Вітае Фармасьютікалс, Інк. Дигідропіролопіридинові інгібітори ror-гамма
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2016133194A1 (ja) 2015-02-20 2016-08-25 第一三共株式会社 がんの併用治療法
US10584102B2 (en) 2015-05-11 2020-03-10 Basf Se Process for preparing 4-amino-pyridazines
UA124228C2 (uk) * 2015-05-11 2021-08-11 Басф Се Спосіб одержання 4-амінопіридазинів
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
MX2018001073A (es) 2015-08-06 2018-06-12 Chimerix Inc Nucleosidos de pirrolopirimidina y analogos de los mismos utiles como agentes antivirales.
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
UA123786C2 (uk) 2016-04-06 2021-06-02 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка mdm2
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
MX2019002212A (es) 2016-08-24 2019-07-08 Arqule Inc Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos.
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
CN108409839B (zh) * 2018-02-13 2020-08-11 中国人民解放军军事科学院军事医学研究院 一种MDM2与p53相互作用的多肽抑制剂及其应用
MA51897A (fr) 2018-02-20 2020-12-30 Agios Pharmaceuticals Inc Procédés d'utilisation de dérivés de benzotriazole trisubstitués
MX2022009528A (es) 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
TR202002325A2 (tr) * 2020-02-17 2021-08-23 Bahcesehir Ueniversitesi Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-4
CN113293046B (zh) * 2021-05-26 2021-11-30 安徽博洋润滑科技有限公司 一种低发尘润滑脂及其制备方法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9201755D0 (en) 1992-01-28 1992-03-11 British Bio Technology Compounds
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
TR200102799T2 (tr) * 1999-03-24 2002-07-22 Anormed Inc. Kemokin alıcı bağlayıcı heterosiklik bileşikler
AU1734401A (en) * 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
SG126006A1 (en) 2000-09-15 2006-10-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
KR100894189B1 (ko) * 2001-03-29 2009-04-22 일라이 릴리 앤드 캄파니 5-ｈｔ6 수용체의 길항제로서의 ｎ-(2-아릴에틸)벤질아민
AU2002357728A1 (en) * 2001-11-09 2003-05-19 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
EP1443937B1 (en) 2001-11-13 2008-06-18 Ortho-McNeil Pharmaceuticals, Inc. Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
RU2305095C2 (ru) 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
GB0428187D0 (en) 2004-12-23 2005-01-26 Univ Liverpool Cancer treatment
ES2345997T3 (es) * 2005-01-14 2010-10-07 Janssen Pharmaceutica Nv Pirazolopiramidinas como inhibidores de las quinasas del ciclo celular.
US20090233905A1 (en) 2006-04-05 2009-09-17 Gregory Peter Burke Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer

Also Published As

Publication number Publication date
JP2008513532A (ja) 2008-05-01
AU2005286525A1 (en) 2006-03-30
TW200626579A (en) 2006-08-01
EP1809622B1 (en) 2010-07-21
US8404683B2 (en) 2013-03-26
ECSP077335A (es) 2007-04-26
SG155941A1 (en) 2009-10-29
US7834016B2 (en) 2010-11-16
US20080039472A1 (en) 2008-02-14
US20110053937A1 (en) 2011-03-03
TWI372758B (en) 2012-09-21
BRPI0515594A (pt) 2008-07-29
NZ553646A (en) 2010-07-30
BRPI0515594B8 (pt) 2021-05-25
CN101023074A (zh) 2007-08-22
AP2007003947A0 (en) 2007-04-30
ZA200702341B (en) 2010-09-29
AR053412A1 (es) 2007-05-09
BRPI0515594B1 (pt) 2020-09-24
CN101023074B (zh) 2012-10-10
IL182009A (en) 2012-06-28
MY136800A (en) 2008-11-28
SI1809622T1 (sl) 2010-11-30
DE602005022472D1 (de) 2010-09-02
ATE474833T1 (de) 2010-08-15
NO20072058L (no) 2007-04-23
ES2349358T3 (es) 2010-12-30
UA91027C2 (ru) 2010-06-25
AU2005286525B2 (en) 2011-06-16
EA012452B1 (ru) 2009-10-30
HRP20100561T1 (hr) 2010-11-30
EP1809622A1 (en) 2007-07-25
CR9081A (es) 2008-11-24
WO2006032631A1 (en) 2006-03-30
KR20070058622A (ko) 2007-06-08
IL182009A0 (en) 2007-07-24
NO341281B1 (no) 2017-10-02
KR101331786B1 (ko) 2013-11-21
AP2446A (en) 2012-08-31
EA200700699A1 (ru) 2007-08-31
MX2007003375A (es) 2007-05-07
CA2579915C (en) 2010-06-22
HK1107651A1 (en) 2008-04-11
CA2579915A1 (en) 2006-03-30
JP5156378B2 (ja) 2013-03-06

Similar Documents

Publication Publication Date Title
DK1809622T3 (da) Inhibitorer af interaktionen mellem MDM2 og P53
DK2203440T3 (da) Inhibitorer af interaktionen mellem MDM2 og P53
NO2017017I1 (no) umeklinidium og vilanterol
DK1780295T3 (da) Svejseforbindelse og svejsemateriale deraf
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
NO20081604L (no) Nitrogeninneholdende heterocyklisk forbindelse og farmasøytisk anvendelse derav
DK1937664T3 (da) Hydrazidforbindelse og pesticid anvendelse af den samme
DE602005012267D1 (de) N von geräten
ATE455629T1 (de) Rasierer und kassetten
ATE542648T1 (de) Rasierer und kassetten
DK1713503T3 (da) Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
DK3321359T3 (da) Variante former af uratoxidase og anvendelse deraf
DK2072051T3 (da) Kombination af azelastin og mometason
DK1771446T3 (da) Azaindolinhibitorer af MTP og APOB
DK1732892T3 (da) Tetrahydrocarbazoler og derivater
NO2016020I2 (no) Imidacloprid og Flumetrin
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
NO20054709L (no) Sammenfoyningssystem og anvendelse av dette
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1879908T3 (da) Immunoglobulinfraktion og fremgangsmåde hertil
DE602005007987D1 (de) achtelung und -entschachtelung
DK1620058T3 (da) Sammensætning til forbedring af kognition og hukommelse
DK1829874T3 (da) Tricyklisk forbindelse og anvendelse deraf
DK1814977T3 (da) Arthrospira-baserede sammensætninger og anvendelser deraf